Flomatrix is an Australian medical device company developing innovative catheters for vascular access. Over 70% of patients admitted to hospital require a peripheral IV cannula (PIVC), however, up to 70% of PIVCs fail too early, costing healthcare systems AU$70 billion. The first Flomatrix device, the FloRamp, has been shown to reduce failure rates compared to the current market-leading PIVC. The FloRamp is a cost comparative device that will save hospitals substantially, whilst improving patient outcomes.